MyoKardia Shares Don't Skip a Beat on $13.1 Billion Acquisition by Bristol Myers Squibb
Source: Streetwise Reports  (10/5/20)
Shares of MyoKardia traded 58% higher after the company reported that Bristol Myers Squibb has agreed to acquire the firm for $13.1 billion, or $225.00 per share in cash. More >

AMAG Pharma Receives $647 Million Takeover Bid from Luxembourg Firm
Source: Streetwise Reports  (10/1/20)
Shares of AMAG Pharmaceuticals traded 44% higher after the company reported it has agreed to be acquired by Covis Group S.à r.l. for $13.75 per share in cash, or approximately $498 million on a fully diluted basis. More >

Pharmaceutical Firm Completes Enrollment of 100 Patients in Phase 2b/3 COVID-19 Clinical Trial
Source: Streetwise Reports  (9/30/20)
Algernon Pharmaceuticals reported it has now enrolled 100 of 150 planned patients in its Phase 2b/3 human study of Ifenprodil for treatment of COVID-19. More >

Life Sciences Firm Finalizes First Sites for Phase 3 COVID-19 Trial
Source: Streetwise Reports  (9/30/20)
Enrollment for the study evaluating Revive Therapeutics' Bucillamine can now begin. More >

GENFIT and LabCorp Form Exclusive Partnership for Novel Liver Disease Diagnostic Test
Source: Streetwise Reports  (9/28/20)
GENFIT SA shares traded 30% higher after the company reported that it entered into an exclusive agreement with LabCorp to commercialize a novel diagnostic liver disease test. More >

Pharmaceutical Firm Reaches 50% Enrollment Mark in Phase 2b/3 Ifenprodil COVID-19 Study
Source: Streetwise Reports  (9/23/20)
Algernon Pharmaceuticals reported it has enrolled the first 75 of 150 patients in a multinational Phase 2b/3 human study of Ifenprodil in treating SARS-CoV-2. More >

California-Based Biotech Receives COVID-19 Trial Clearance
Source: Streetwise Reports  (9/23/20)
The timeline and next steps for Equillium's proposed Phase 3 clinical study are outlined in an H.C. Wainwright & Co. report. More >

Biotech to Develop Alzheimer's Disease Vaccine Using Proprietary Peptide Antigens
Source: Streetwise Reports  (9/23/20)
ProMIS Neurosciences has demonstrated positive outcomes in proof-of-concept studies. More >

AIM ImmunoTech Achieves 200% Increase in Survival Results in Late-Stage Pancreatic Cancer Study
Source: Streetwise Reports  (9/22/20)
AIM ImmunoTech shares traded 20% higher after the firm reported it attained statistically significant, two-fold higher survival results in pancreatic cancer from research conducted at Erasmus University Medical Center in the Netherlands. More >

FDA Grants Ampio Pharma IND and Approves Phase 1 Trial for Inhaled Ampion in COVID-19 Patients
Source: Streetwise Reports  (9/21/20)
Ampio Pharmaceuticals traded 15% higher reaching a new 52-week high after the company reported that the U.S. FDA granted an IND and approved the clinical trial protocol for inhaled Ampion for use in COVID-19 patients with respiratory distress. More >

Biopharma Advances Development of Psilocybin-Based Therapeutics
Source: Streetwise Reports  (9/21/20)
Revive Therapeutics provides an update on its psychedelics therapeutics programs. More >

Pharma Greenlighted to Continue Multinational COVID-19 Study
Source: Streetwise Reports  (9/18/20)
This confirms the safety of NP-120, the drug Algernon Pharmaceuticals is evaluating in this human trial. More >

Expanded Access Protocol for Compassionate Use Approved for Patients with Severe COVID-19
Source: Streetwise Reports  (9/17/20)
Through this program of Revive Therapeutics, qualifying patients will receive Bucillamine, and the biopharma will obtain safety and efficacy data. More >

Sorrento Receives FDA Clearance to Proceed with Phase 1 COVID-19 Neutralizing Antibody Trial
Source: Streetwise Reports  (9/17/20)
Sorrento Therapeutics shares traded more than 10% higher after the company reported it received FDA approval to proceed with its Phase 1 clinical trial of STI-1499 (COVI-GUARD) Neutralizing Antibody in hospitalized COVID-19 patients. More >

Further Trial Data Analyses 'Reinforce' Profile of Biopharma's Multiple Sclerosis Drug
Source: Streetwise Reports  (9/16/20)
The confirmatory results concerning Immunic's lead drug candidate IMU-838 are presented in an H.C. Wainwright & Co. report. More >

Arrowhead Shares Point Higher on Positive Interim Data in Phase 2 Liver Disease Trial
Source: Streetwise Reports  (9/16/20)
Shares of Arrowhead Pharmaceuticals traded 48% higher after the firm reported positive interim results from its Phase 2 study of ARO-AAT in patients with alpha-1 antitrypsin deficiency liver disease. More >

Marinus Pharma Shares Sail 50% Higher on Phase 3 Genetic Epilepsy Trial Results
Source: Streetwise Reports  (9/15/20)
Marinus Pharmaceuticals shares reached a new 52-week high price after the company reported it achieved the primary endpoint in its Phase 3 Study of ganaxolone for CDKL5 deficiency disorder, a rare type of genetic epilepsy. More >

Immunomedics' Shares Double on Gilead's $21 Billion Buyout Offer
Source: Streetwise Reports  (9/14/20)
Shares of Immunomedics Inc. traded 100% higher after the company reported that it has agreed to be acquired by Gilead Sciences for $88 per share in cash. More >

Life Sciences Company Posts Record Q3 Revenue Due to Successful Recurring Purchase Model
Source: Streetwise Reports  (9/9/20)
Avivagen Inc. reported unaudited financial results for Q3/20 that included record revenue and product sales volumes that nearly eclipsed FY/19 levels. More >

Intra-Cellular Shares Soar on Positive Bipolar Depression Study Findings
Source: Streetwise Reports  (9/9/20)
Shares of Intra-Cellular Therapies traded 77% higher after the company reported that positive data from its Phase 3 Study 402 will form the basis for its sNDA for lumateperone in treating bipolar depression in patients with Bipolar I or II disorder as monotherapy and adjunctive therapy. More >

Trillium Shares Get Boost from Dose Escalation Trial Data and Pfizer's $25 Million Equity Investment
Source: Streetwise Reports  (9/9/20)
Trillium Therapeutics shares traded 37% higher after the company reported updated results from its ongoing TTI-622 and TTI-621 Dose Escalation Studies along with a $25 million equity investment from Pfizer Inc. More >

Biopharma Achieves 'Big Phase 3 Win' for its Pediatric Intrahepatic Cholestasis Drug
Source: Streetwise Reports  (9/9/20)
The recent study results of Albireo Pharma's lead therapeutic candidate are discussed in an H.C. Wainwright & Co. report. More >

Biotech Partners with University to Evaluate Psilocybin for Treating Methamphetamine Use Disorder
Source: Streetwise Reports  (9/4/20)
Revive Therapeutics reported it has entered into clinical trial agreement with the University of Wisconsin-Madison to evaluate the use of psilocybin for the treatment of methamphetamine use disorder. More >

Life Sciences Firm Gains Protocol Approval for Phase 3 COVID-19 Study
Source: Streetwise Reports  (9/2/20)
Revive Therapeutics reported that a renowned independent institutional review board has approved its proposed Phase 3 clinical trial protocol for Bucillamine in COVID-19. More >

Aimmune Therapeutics Shares Soar on Nestlé Health Science's $2.6 Billion Buyout
Source: Streetwise Reports  (8/31/20)
Aimmune Therapeutics shares traded 170% higher after the company reported it entered into a definitive agreement to be acquired by Nestlé for $34.50 per share in cash. More >